Journal of Food and Nutrition Research
ISSN (Print): 2333-1119 ISSN (Online): 2333-1240 Website: http://www.sciepub.com/journal/jfnr Editor-in-chief: Prabhat Kumar Mandal
Open Access
Journal Browser
Go
Journal of Food and Nutrition Research. 2019, 7(12), 815-820
DOI: 10.12691/jfnr-7-12-1
Open AccessArticle

The Effect of Eicosapentanoic Acid Administration on Inflammatory Markers and Clinical Outcome of Patients with Major Depression: A Pilot Study

El Baz A.H.1, , El Wakeel L.M.2, El-Shafie T. M3 and Zaki M.A1

1Department of Clinical Pharmacy, Ahram Canadian University

2Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University

3Department of Psychiatry, Faculty of Medicine, Al Azhar University

Pub. Date: December 10, 2019

Cite this paper:
El Baz A.H., El Wakeel L.M., El-Shafie T. M and Zaki M.A. The Effect of Eicosapentanoic Acid Administration on Inflammatory Markers and Clinical Outcome of Patients with Major Depression: A Pilot Study. Journal of Food and Nutrition Research. 2019; 7(12):815-820. doi: 10.12691/jfnr-7-12-1

Abstract

Background. Major depressive disorder (MDD) affects approximately 10% of the world population and leads to significant disability. The current study aimed to evaluate the impact of Omega3 polyunsaturated fatty acids (PUFAs) administration on the clinical outcome and inflammatory markers of patients with depression. Patients and Methods. A prospective, randomized controlled study conducted at the outpatient clinics of Alzahraa University Hospital, Cairo, Egypt on patients diagnosed with depression according to a strict inclusion and exclusion criteria. Forty-two patients were randomly assigned to either; Group1; (intervention n=21); received the prescribed antidepressant + omega3 (2100mg) for 8 weeks, or Group 2; (control, n=21); received the prescribed antidepressant only for 8 weeks. Baseline evaluation and 8-week assessment included; patient demographic data collection, history taking and clinical assessment of Diagnostic statistical manual for mental disorders, fifth edition (DSM-5) criteria & Hamilton rating scale for depression (HAM-D score). Laboratory assessment included tumor necrosis factor-α (TNF-α) levels. Patients were followed up regularly every week for 8 weeks for the occurrence of side effects due to antidepressants/ Omega 3 and compliance with medications. Results. The 2 groups were comparable at baseline. The test group showed a significant improvement in the HAM-D score & a reduction in TNF-α levels from baseline values and versus the control. There was no significant difference in the reported side effects between the 2 groups. Conclusion. Omega -3 PUFAs administration at a dose of 2100 mg for 8 weeks, improved depression symptoms and reduced inflammatory markers & was well tolerated.

Keywords:
Omega-3 PUFAs depression TNF-α EPA/DHA

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Song C, Shieh CH, Wu YS, Kalueff A, Gaikwad S, Su KP. The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer's disease: Acting separately or synergistically? Prog Lipid Res. 2016; 62: 41-54.
 
[2]  Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annual review of public health. 2013; 34: 119-38.
 
[3]  Beshai S, Dobson KS, Adel A, Hanna N. A cross-cultural study of the cognitive model of depression: cognitive experiences converge between Egypt and Canada. PloS one. 2016; 11(3): e0150699.
 
[4]  Qureshi NA, Al-Bedah AM. Mood disorders and complementary and alternative medicine: a literature review. Neuropsychiatric disease and treatment. 2013;9(639):58.
 
[5]  Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. Journal of clinical psychopharmacology. 2012; 32(1): 61-4.
 
[6]  Grosso G, Galvano F, Marventano S, Malaguarnera M, Bucolo C, Drago F, et al. Omega-3 fatty acids and depression: scientific evidence and biological mechanisms. Oxidative medicine and cellular longevity. 2014; 2014.
 
[7]  Hennebelle M, Balasse L, Latour A, Champeil-Potokar G, Denis S, Lavialle M, et al. Influence of omega-3 fatty acid status on the way rats adapt to chronic restraint stress. PloS one. 2012; 7(7): e42142.
 
[8]  Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis: effects of eicosapentaenoic acid in clinical trials in depression. The Journal of clinical psychiatry. 2011; 72(12): 1577.
 
[9]  Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013; 150(2): 384-8.
 
[10]  Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS medicine. 2013; 10(11): e1001547.
 
[11]  Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Behavioral Neurobiology of Depression and Its Treatment: Springer; 2012. p. 135-51.
 
[12]  Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain, behavior, and immunity. 2011; 25(8): 1725-34.
 
[13]  Gharekhani A, Khatami MR, Dashti-Khavidaki S, Razeghi E, Noorbala AA, Hashemi-Nazari SS, et al. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial. European journal of clinical pharmacology. 2014; 70(6): 655-65.
 
[14]  Mocking RJ, Assies J, Bot M, Jansen EH, Schene AH, Pouwer F. Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: a randomized controlled trial. PloS one. 2012; 7(11): e49431.
 
[15]  Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Molecular psychiatry. 2016; 21(1): 71-9.
 
[16]  Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. Jama. 2009; 302(15): 1651-7.
 
[17]  Kris-Etherton PM, Harris WS, Appel LJ, Nutrition C. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arteriosclerosis, thrombosis, and vascular biology. 2003; 23(2): e20-30.